[HTML][HTML] Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
Background Merkel cell carcinoma (MCC) is an aggressive skin cancer associated with poor
survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of …
survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of …
Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy
PURPOSE Merkel cell carcinoma (MCC) is an aggressive skin cancer often caused by the
Merkel cell polyomavirus. Clinical trials of programmed cell death-1 pathway inhibitors for …
Merkel cell polyomavirus. Clinical trials of programmed cell death-1 pathway inhibitors for …
[HTML][HTML] Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series
J LoPiccolo, MD Schollenberger, S Dakhil… - … for immunotherapy of …, 2019 - Springer
Merkel cell carcinoma (MCC) is a rare but clinically aggressive cancer with a high mortality
rate. In recent years, antibodies blocking the interactions among PD-1 and its ligands have …
rate. In recent years, antibodies blocking the interactions among PD-1 and its ligands have …
[HTML][HTML] Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after≥ 1 year of follow-up: JAVELIN Merkel 200, a phase 2 …
HL Kaufman, JS Russell, O Hamid, S Bhatia… - … for immunotherapy of …, 2018 - Springer
Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with
poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial …
poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial …
PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma
Background Merkel-cell carcinoma is an aggressive skin cancer that is linked to exposure to
ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell carcinoma …
ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell carcinoma …
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
HL Kaufman, J Russell, O Hamid, S Bhatia… - The lancet …, 2016 - thelancet.com
Background Merkel cell carcinoma is a rare, aggressive skin cancer with poor prognosis in
patients with advanced disease. Current standard care uses various cytotoxic chemotherapy …
patients with advanced disease. Current standard care uses various cytotoxic chemotherapy …
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a …
Background Merkel cell carcinoma (MCC) is an immunogenic but aggressive skin cancer.
Even after complete resection and radiation, relapse rates are high. PD-1 and PD-L1 …
Even after complete resection and radiation, relapse rates are high. PD-1 and PD-L1 …
[HTML][HTML] Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
V Glutsch, H Kneitz, A Gesierich, M Goebeler… - Cancer Immunology …, 2021 - Springer
Background Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine
cutaneous malignancy with poor prognosis. In Europe, approved systemic therapies are …
cutaneous malignancy with poor prognosis. In Europe, approved systemic therapies are …
[HTML][HTML] Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline–Update 2022
ML Gauci, C Aristei, JC Becker, A Blom… - European Journal of …, 2022 - Elsevier
Merkel cell carcinoma (MCC) is a rare skin cancer, accounting for less than 1% of all
cutaneous malignancies. It is found predominantly in white populations and risk factors …
cutaneous malignancies. It is found predominantly in white populations and risk factors …
[HTML][HTML] Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN …
Background Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with
a high risk of metastasis. In 2017, avelumab (anti–programmed death-ligand 1 (PD-L1)) …
a high risk of metastasis. In 2017, avelumab (anti–programmed death-ligand 1 (PD-L1)) …